Search
for
Sort by
Research 61–90 of 1000+
- Editor's Picks February 2021
- Game Changers: Blockbuster Small-Molecule Drugs Approved by the FDA in 2024
- TNF inhibitor induced alopecia: an unusual form of psoriasiform alopecia that breaks the Renbök mold
- Zinc in skin pathology and care
- Athena: Specialty Certificate Examination case for general dermatology and dermatology in primary healthcare
- Dermatologic therapy: December 1987 to December 1988
- Ann Robinson’s research reviews —12 May 2022
- Dermatologic therapy: December 1986 to December 1987
- Dermatological manifestations associated with COVID‐19: A comprehensive review of the current knowledge
- Utility of azathioprine, methotrexate and cyclosporine as steroid‐sparing agents in chronic alopecia areata: a retrospective study of continuation rates in 138 patients
- TREATMENT OF SEVERE ALOPECIA AREATA USING METHOTREXATE AS AN ADJUNCTIVE DRUG IN COMBINATION WITH INTRAVENOUS AND ORAL CORTICOSTEROID
- Treatment of severe alopecia areata with baricitinib
- Treatment of Severe Alopecia Areata: Combination Therapy Using Systemic Cyclosporine A with Low Dose Corticosteroids
- Ritlecitinib in severe alopecia areata: a profile of its use
- Tofacitinib for the treatment of severe alopecia areata and variants: A retrospective cohort study of 90 patients
- High frequency of cutaneous manifestations including vitiligo and alopecia areata in a prospective cohort of patients with chronic graft-vs-host disease
- Appearance of alopecia areata during treatment with tildrakizumab for severe palmoplantar psoriasis
- Holistic management of chronic hair loss with alopecia areata in a young female treated at Dr. Batra’s® – A classical homeopathic case study
- Circulating MicroRNA Signatures in Severe Alopecia Areata: Diagnostic Discrimination, Pathway Analysis, and Therapeutic Implications
- Baricitinib in the Management of Severe Alopecia Areata: A Report of Two Cases With Sustained Clinical Response
- Integrated safety analysis of baricitinib in adults with severe alopecia areata from two randomized clinical trials
- Significant improvement with ivarmacitinib after suboptimal response to tofacitinib in severe alopecia areata: a case report and literature review
- Reduced level of 25-hydroxyvitamin D in chronic/relapsing Alopecia Areata
- Oral ruxolitinib induces hair regrowth in patients with moderate-to-severe alopecia areata
- A Cost-per-Responder Analysis of Ritlecitinib vs Baricitinib in Severe Alopecia Areata
- Case Series and Literature Review on Tofacitinib for Treating Severe Alopecia Areata
- A Review of Adverse Cutaneous Drug Reactions Resulting from the Use of Interferon and Ribavirin
- Abrocitinib in the Treatment of Severe Alopecia Areata in a Pediatric Patient: A Case Report
- Assessing a measure for Quality of Life in patients with severe Alopecia Areata: a multicentric Italian study
- Abrocitinib Improved Dupilumab-Resistant Severe Atopic Dermatitis with Comorbid Mild Alopecia Areata in a 12-Year-Old Boy: A Case Report with 1-Year Follow-Up